The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy
Authors:
- Giselle BleeckerGBGiselle Bleecker
- Jeffrey CrawfordJCJeffrey Crawford
- Ronald StollerRSRonald Stoller
- Michael StraussMSMichael Strauss
- 1 January 1993
- journal article
- clinical trial
- Published by Elsevier in European Journal of Cancer
- Vol. 29, S23-S30
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1992
- Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating FactorNew England Journal of Medicine, 1992
- Reduction by Granulocyte Colony-Stimulating Factor of Fever and Neutropenia Induced by Chemotherapy in Patients with Small-Cell Lung CancerNew England Journal of Medicine, 1991
- The National Economic Burden of Cancer: An UpdateJNCI: Journal of the National Cancer Institute, 1990
- Effect of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor on Chemotherapy-Induced MyelosuppressionNew England Journal of Medicine, 1988
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)Blood, 1988
- Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancerBritish Journal of Cancer, 1987
- High-dose induction chemotherapy with cyclophosphamide, etoposide, and cisplatin for extensive-stage small-cell lung cancer.Journal of Clinical Oncology, 1987
- The Distinction Between Cost and ChargesAnnals of Internal Medicine, 1982